SEATTLE, Dec. 11, 2018 /PRNewswire/ — LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement with Miloftalmica to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Italy. Miloftalmica is leading the Italian ophthalmology… Continue reading

Posted on December 12th, 2018 in Press Releases | Comments Off on LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy

24 October 2018, Dunfermline, Scotland; Optos Plc, a subsidiary of Nikon Corporation, Japan and the only ultra-widefield retinal imaging company for eye care is pleased to announce an exclusive distribution agreement in Europe and Australia for MacuLogix and LumiThera products. By entering this arrangement, we now offer a comprehensive solution to visualize, identify, and treat… Continue reading

Posted on October 24th, 2018 in Press Releases | Comments Off on Optos Announces Collaboration for Monitoring and Treating Dry Age-Related Macular Degeneration in Europe

SEATTLE, Oct. 24, 2018 /PRNewswire/ — LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement with Optos Plc, a division of Nikon, Inc., Japan to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in… Continue reading

Posted on October 24th, 2018 in Press Releases | Comments Off on LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe

SEATTLE, Oct. 19, 2018 /PRNewswire/ — LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting on October 25, 2018, in Chicago, IL. OIS unites industry, entrepreneurial and… Continue reading

Posted on October 22nd, 2018 in Press Releases | Comments Off on LumiThera, Inc. Selected to Present at the Ophthalmology Innovation Summit 2018 at the American Academy of Ophthalmology, Chicago, IL

SEATTLE, Sept 14, 2018 /PRNewswire/ — LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced that it will participate in the combined exhibition of the 18th EURETINA Annual Meeting and the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in… Continue reading

Posted on September 16th, 2018 in Press Releases | Comments Off on LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the European Society of Retina Specialists (EURETINA) in Vienna, Austria

SEATTLE, June 22, 2018 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company focused on developing non-invasive Photobiomodulation (PBM) therapies for ocular disorders and disease, announced CE Mark Certification for the European Union (EU) for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System. The “CE” mark is the… Continue reading

Posted on June 25th, 2018 in Press Releases | Comments Off on LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark

SEATTLE, May 1, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive Photobiomodulation (PBM) therapies for ocular disorders and disease, presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System. The LIGHTSITE I data… Continue reading

Posted on May 1st, 2018 in Press Releases | Comments Off on LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data

SEATTLE, March 13, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural… Continue reading

Posted on March 16th, 2018 in Press Releases | Comments Off on LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

SEATTLE, Feb. 5, 2018 /PRNewswire/ — LumiThera, a clinical stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will participate in the 7th Annual Glaucoma 360 New Horizons Forum being held on Friday, February 9, 2018 at The Palace Hotel, in San Francisco. This meeting… Continue reading

Posted on February 5th, 2018 in Press Releases | Comments Off on LumiThera, Inc. to Participate in the 2018 Glaucoma 360 in San Francisco

SEATTLE, Jan. 4, 2018 /PRNewswire/ — LumiThera a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Digital Medicine and MedTech ShowcaseTM 2018, to be held January 8-10 during the most important week in healthcare at the Parc 55… Continue reading

Posted on January 5th, 2018 in Press Releases | Comments Off on LumiThera to Present at the Digital Medicine and MedTech ShowcaseTM Annual Conference on January 10, 2018